More than a decade ago ciprofloxacin, the first quinolone with broad indications, was released for clinical use in the United States. The release of ofloxacin, which also had broad applications, followed not long thereafter. Since that time there has been extensive use of these 2 agents and more limited use of other quinolones, such as norfloxacin, enoxacin, and lomefloxacin, which were limited to treatment of infections of the genitourinary tract. Applications of these quinolones largely employed their potent activities against gram-negative bacteria [1, 2] .
More than a decade ago ciprofloxacin, the first quinolone with broad indications, was released for clinical use in the United States. The release of ofloxacin, which also had broad applications, followed not long thereafter. Since that time there has been extensive use of these 2 agents and more limited use of other quinolones, such as norfloxacin, enoxacin, and lomefloxacin, which were limited to treatment of infections of the genitourinary tract. Applications of these quinolones largely employed their potent activities against gram-negative bacteria [1, 2] .
This article focuses on information developed in the past 4 years on the 4 most recently released quinolones-levofloxacin, sparfloxacin, grepafloxacin, and trovafloxacin [3] [4] [5] [6] [7] [8] -and their spectrum of activity, pharmacokinetics, tolerability, and clinical applications. It also focuses on new applications of the older quinolones. Issues of quinolone resistance related to expanding uses of quinolones will also be discussed.
Spectrum of Activity
The newer fluoroquinolones have retained much of the activity of ciprofloxacin and ofloxacin against enteric gramnegative bacteria, but none is more potent than ciprofloxacin against these pathogens or against Pseudomonas aeruginosa. Levofloxacin is the active stereoisomer of the racemic mixture of the 2 stereoisomers that make up ofloxacin and thus is generally 2-fold more potent than ofloxacin [3] . Trovafloxacin [9] and, to a lesser extent, levofloxacin generally have gram-negative coverage similar to that of ciprofloxacin, but both may be less active against some strains of P. aeruginosa.
There may also be gaps in trovafloxacin's coverage of some strains of Providencia species, Proteus species, and Serratia marcescens. There are also gaps in the gram-negative coverage of sparfloxacin and grepafloxacin. Sparfloxacin [10, 11] has only limited potency against P. aeruginosa, S. marcescens, Citrobacter freundii, and Proteus vulgaris; and grepafloxacin [12] lacks sufficient activity against P. aeruginosa, S. marcescens, Providencia stuartii, and Acinetobacter baumanii among gram-negative bacteria.
Like ciprofloxacin and ofloxacin, the newer agents have excellent potency against genital pathogens, including Neisseria gonorrhoeae, Chlamydia trachomatis, and Mycoplasma hominis. Their clinical efficacy in the treatment of genital chlamydial infections may differ, however, as discussed below.
Against respiratory pathogens, all of the newer quinolones, such as ciprofloxacin and ofloxacin, are highly potent against Haemophilus influenzae and Moraxella catarrhalis. However, these agents exhibit greater potency than ciprofloxacin and ofloxacin against Streptococcus pneumoniae, with MIC 90 values of 1-2 mg/mL for levofloxacin [13] , 0.25-0.5 mg/mL for sparfloxacin [14] and grepafloxacin [15] , and 0.12-0.25 mg/mL for trovafloxacin [16] . For this reason, all have been developed for treatment of respiratory tract infections, as discussed below. Other respiratory pathogens, such as Legionella pneumophila, Mycoplasma pneumoniae, and Chlamydia pneumoniae, are also highly susceptible to all 4 newer quinolones.
Although the newer quinolones all have greater potency than ciprofloxacin against gram-positive cocci in addition to S. pneumoniae, they will have a more limited role in treatment of staphylococcal and enterococcal infections because of marginal potency or acquired resistance. Among staphylococci, most methicillin-susceptible strains of Staphylococcus aureus are susceptible to levofloxacin (MIC 90 , 0.5-1 mg/mL) [17] , sparfloxacin (MIC 90 , 0.06-0.125 mg/mL) [18] , grepafloxacin (MIC 90 , 0.12 mg/ mL) [12] , and trovafloxacin (MIC 90 , 0.03-0.125 mg/mL) [19] . In contrast, many methicillin-resistant strains of S. aureus have acquired high-level resistance to ciprofloxacin that causes substantial cross-resistance to all of the newer agents.
These same patterns of differing quinolone susceptibility have been seen with methicillin-susceptible and -resistant strains of coagulase-negative staphylococci. Activity against enterococci is marginal, with MIC 90 values of 3.1 mg/mL for levofloxacin [20] , 1-2 mg/mL for sparfloxacin [21] , 2 to 14 mg/mL for grepafloxacin [12] , and 1-32 mg/mL for trovafloxacin [9, 19] . Against vancomycin-resistant enterococci (which in the United States are often Enterococcus faecium), MICs often are at the high end of these ranges.
Against Mycobacterium tuberculosis, levofloxacin appears to have good activity (MIC, 0.5-0.75 mg/mL) [22] , as does sparfloxacin (MIC 90 , 0.5 mg/mL) [23] . Information is not available on grepafloxacin, and trovafloxacin has poor activity (MIC 90 , 32 mg/mL) [9] . Only trovafloxacin (of all available quinolones) has sufficient activity against anaerobic bacteria for clinical applicability [24] .
Most species of anaerobic bacteria tested have been inhibited by р1 mg/mL, including Bacteroides fragilis, against which trovafloxacin was 32-to 64-fold more active than ciprofloxacin. Some strains of Bacteroides thetaiotaomicron had somewhat higher MICs of 2 mg/mL.
Pharmacokinetics
The 4 newest fluoroquinolones vary in their pharmacokinetics (table 1) . Levofloxacin and trovafloxacin both have oral and iv formulations that allow direct estimates of oral bioavailability, with values 195% for levofloxacin [25] and 88% for trovafloxacin [26] . Maximum concentrations of drug in serum (C max ) are highest for levofloxacin (5.7-6.4 mg/mL) and lowest for sparfloxacin (1.1 mg/mL) with usual dosing [27] . All of the newer quinolones have longer half-lives of elimination than the earlier agents and are given as single daily doses, with sparfloxacin having the longest half-life (20 h) [27] and levofloxacin the shortest (6-8 h) [25] .
Although levofloxacin has only a slightly longer half-life than ofloxacin, it is given at a somewhat higher dose (with a 2-fold greater potency) once rather than twice a day. This dosage is based on pharmacodynamic modeling of quinolones that indicates concentration-dependent bacterial killing and postantibiotic effects [28] , similar to what is seen for aminoglycosides. The half-lives of sparfloxacin [27] , grepafloxacin [29] , and trovafloxacin [26, 30] all support once-daily dosing, and for sparfloxacin an initial, higher loading dose of 400 mg is recommended to reduce the time to attainment of steady-state concentrations in serum.
Routes of elimination differ among the newest quinolones. Levofloxacin, like ofloxacin, is largely excreted by renal routes, which include both glomerular filtration and tubular secretion. Nonrenal routes of elimination predominate for sparfloxacin, grepafloxacin, and trovafloxacin. For sparfloxacin, hepatic glucuronidation appears to be the main route of elimination, with glucuronide conjugates found in serum, urine, and bile [31] . Grepafloxacin is excreted largely in the feces by biliary excretion or transintestinal elimination, with only limited (!10%) formation of metabolites (glucuronide and sulfate conjugates and a metabolite with an oxidized piperazinyl ring) [29] . Trovafloxacin is eliminated primarily by biliary excretion, with additional hepatic metabolism by glucuronidation, N-acetylation, and N-sulfoconjugation, but minimal oxidative metabolism by hepatic cytochrome P450 enzymes [32] .
Dosage adjustments in cases of renal and hepatic failure differ (table 2) . No adjustments of dosages of grepafloxacin and trovafloxacin are necessary when renal failure occurs [33] . The doses of levofloxacin and sparfloxacin should be reduced for patients with creatinine clearances !50 mL/min [3, 34] . With use of sparfloxacin, the glucuronide conjugate accumulates in patients with renal failure. In patients with hepatic failure (without renal dysfunction), no adjustments in dosing of levofloxacin and sparfloxacin are generally necessary.
With use of grepafloxacin there are 36% and 48% increases in serum concentrations in patients with mild and moderate impairment in liver function, respectively, and the manufacturer recommends that the drug not be given to any patient with hepatic failure [35] . For trovafloxacin, the manufacturer recommends that dosing be reduced in the presence of mild to moderate hepatic dysfunction. In light of the hepatotoxic potential of trovafloxacin (see below), however, administration of trovafloxacin to such patients should probably be avoided
Interactions with Other Drugs
All of the newest quinolones, like the earlier members of the class, form complexes with multivalent cations that impair their oral absorption. Therefore, antacids, sucralfate, and other multivalent cation-containing preparations should not be given concurrently with any quinolone; instead, dosing should be staggered by at least 2 h. H 2 -receptor antagonists do not affect absorption. Cisapride increases the rate of absorption of sparfloxacin but does not affect its overall bioavailability [36] . Omeprazole reduces the bioavailability of oral trovafloxacin slightly (18%) but is not known to affect the bioavailability of other quinolones [37] . Intravenous morphine also reduces the oral absorption of trovafloxacin by 30%-45%, presumably by reducing splanchnic blood flow [38] . Of the 4 newest quinolones, only grepafloxacin has a clinically important interaction with theophylline, reducing its elimination and resulting in increases of 28% (400-mg dose) to 82% (600-mg dose) in the C max in serum [39] .
Adverse Effects
The side-effect profiles of quinolones have been recently reviewed [40] . In most cases, the adverse-effect profiles of different quinolones have not been compared directly in the same patient population. Gastrointestinal adverse effects such as nausea, vomiting, diarrhea, and abdominal pain generally are the most common category of adverse effects of quinolones, with rates in the range of 1%-4% of patients overall. An exception is grepafloxacin, which was associated with rates of nausea of 10%-22%, significantly higher than rates associated with ciprofloxacin [41] . Gastrointestinal symptoms were more frequent with the 600-mg dose than with the 400-mg dose. Taste perversion (described as a bitter taste in the mouth) was also reported by 13%-27% of patients receiving grepafloxacin [6] .
The next most common category of adverse effects has been related to the CNS, with insomnia, dizziness, and headache reported most often. Rates have been low for levofloxacin (1%-2%) and sparfloxacin (2%) and similar for grepafloxacin and ciprofloxacin (6%-9%). Dizziness was reported more frequently with use of trovafloxacin (2%-11%) than with comparison agents (3%) [8] . This symptom was generally mild, tended to decrease with continued dosing, and led to discontinuation of the dosing for only 2% of patients. The manufacturer notes that dizziness is reduced if the single daily dose is given at bedtime. Photosensitivity reactions are rare with levofloxacin, grepafloxacin, and trovafloxacin. In contrast, sparfloxacin, which contains a halide substituent at position 8 that is known to be associated with phototoxicity, was associated with significantly higher rates of photosensitivity reactions (7.9%) than were comparison agents in North American trials [40] . Reactions were generally mild and resolved over a mean of 6 days [42] . No case occurred 13 days after completion of therapy. Light in the ultraviolet A range (320-420 nm), which is associated with these reactions, is not blocked by many sunscreens, which often contain only ultraviolet B blockers. Products containing ultraviolet A blockers such as octocrylene or Parsol 1789 (Person and Covey; Glendale, CA) may afford some protection [40] .
Prolongation of the QT c (the interval [corrected for heart rate] between the beginning of the QRS complex to the end of the T wave) on the electrocardiogram has been associated with sparfloxacin and, to a lesser extent, grepafloxacin, but not with levofloxacin and trovafloxacin. With sparfloxacin, this effect is dose-related (2% at 100 mg q.d. and 8% at 400 mg q.d.) and similar in magnitude to that occurring with erythromycin (3.7%) [43] . Potentially clinically important prolongation of the QT c of у500 msec in 1.2%-3% of patients in clinical trials was reported, but arrhythmias have been rare with serious cardiovascular events, including some with ventricular tachycardia, occurring in ∼1 in 100,000 courses of treatment in postmarketing surveillance. Grepafloxacin was recently withdrawn by the manufacturer because several patients receiving the drug have experienced cardiovascular events. Use of sparfloxacin and grepafloxacin is contraindicated for patients with known prolongation of the QT c or torsades de pointe and for those patients taking other drugs known to prolong the QT c .
Laboratory abnormalities have been uncommonly reported for patients taking quinolones. This paucity of abnormalities was also noted overall in clinical trials of trovafloxacin. In contrast, in 1 unpublished study of patients with chronic pros-tatitis, trovafloxacin given for 28 days was associated in 9% of patients with asymptomatic increases in hepatic transaminase levels (to у3 times the upper limit of normal), which resolved within 2 months after discontinuation of therapy.
Subsequently, in postmarketing surveillance, there have been reports to the US Food and Drug Administration (FDA) of 140 symptomatic hepatic reactions in patients receiving trovafloxacin, among 2.5 million prescription recipients, for a reporting incidence of 1 : 18,000. Among these were 14 cases of acute liver failure resulting in 6 deaths, 5 of which were due to liver failure. One additional death occurred among the 4 patients who received liver transplants.
Because of these reports, the FDA on 9 June 1999 issued a Public Health Advisory with interim recommendations that trovafloxacin be used only for patients with life-or limb-threatening infections (nosocomial pneumonia, community-acquired pneumonia, complicated intra-abdominal infections, gynecologic and pelvic infections, and complicated skin and skin structure infections [including diabetic foot infections]), whose physicians believe that the benefits of trovafloxacin therapy outweigh the risks. Although the risk of hepatotoxicity appeared to be higher with courses of therapy exceeding 2 weeks, liver failure was reported to occur in 1 patient receiving treatment for only 2 days, making uncertain the value of monitoring serum transaminase levels to reduce the risks. The mechanism of this rare but severe toxicity have not yet been determined.
Clinical Applications

Urinary tract infections (UTIs).
Concentrations of ciprofloxacin and ofloxacin in urine are high, as are those of levofloxacin, reflecting their dominant renal routes of elimination (renal clearance, 50%-70% of total clearance). Concentrations of sparfloxacin, grepafloxacin, and trovafloxacin in urine are lower than those of other fluoroquinolones, because their elimination is largely by nonrenal routes (renal clearance, 5%-13% of total clearance). For uncomplicated cystitis in young women, published data are available only for sparfloxacin, which when used at full doses (a 400-mg initial dose and then 200 mg q.d.) for a total of 3 days was comparable with ofloxacin (200 mg b.i.d.) given for 3 days, yielding similar clinical and microbiological cure rates [44] .
These results probably reflect the high level of susceptibility of the Escherichia coli pathogens that predominated (86%) in this study. Sparfloxacin given in a lower dose (a 200-mg initial dose and then 100 mg q.d.), however, was less effective than was ciprofloxacin (500 mg b.i.d.) for treatment of patients with complicated UTIs [45] . No differences in the rates of eradication of E. coli were seen, but sparfloxacin was inferior in eliminating other members of the Enterobacteriaceae, Pseudomonas aeruginosa, and enterococci that are more commonly pathogens in patients with complicated infections.
Levofloxacin has been studied for the treatment of patients with acute uncomplicated pyelonephritis, mainly young women with E. coli infections [46] . ] during follow-up, suggesting the possibility that higher P = .31 doses or longer courses of therapy should be considered for patients with acute pyelonephritis.
No published data are available on the use of grepafloxacin and trovafloxacin for treatment of UTIs. Their low concentrations in urine and those of sparfloxacin would suggest, however, that sparfloxacin, grepafloxacin, and trovafloxacin offer no advantage over ciprofloxacin or levofloxacin for UTIs caused by gram-negative bacteria.
Sexually transmitted diseases. For treatment of uncomplicated gonorrhea, sparfloxacin (200 mg), grepafloxacin (400 mg), and trovafloxacin (100 mg) have all been shown to be highly effective, when given as single doses, in eradicating N. gonorrhoeae [47] [48] [49] . Small numbers of rectal and pharyngeal infections were also eradicated by grepafloxacin and trovafloxacin. The efficacy of sparfloxacin was virtually identical to that of ciprofloxacin (250 mg; 99% vs. 98%), and the efficacy of trovafloxacin was similar to that of ofloxacin (400 mg; 99% vs. 100%). Thus it is not clear whether the newer agents offer any advantage over the older agents for treatment of uncomplicated gonorrhea.
Information on efficacy of the newer agents in patients infected with strains of N. gonorrhoeae with reduced susceptibility to ciprofloxacin would be valuable. No published data are available on the use of levofloxacin for treatment of gonococcal infections, but the high efficacy of ofloxacin [50] would suggest that levofloxacin would also be effective.
Against C. trachomatis, single doses of sparfloxacin and grepafloxacin, like single doses of other quinolones, were poorly effective. Cultures remained positive for C. trachomatis for 2 of 5 patients given single doses of sparfloxacin and 8 of 19 patients given single doses of grepafloxacin. More prolonged courses of both of these agents, like a 7-day course of ofloxacin [51] , however, were effective in eradicating genital chlamydia.
For chlamydial urethritis in men, sparfloxacin (200 mg on day 1 and then 100 mg q.d.) given for 7 days was as effective as a 7-day course of doxycycline (97% vs. 96% eradication), but a 3-day course of sparfloxacin was somewhat less effective (88%) [52] . In women with uncomplicated chlamydial cervicitis, 7-day courses of grepafloxacin (400 mg q.d.) and doxycycline also had similar efficacy (96% vs. 99%) [53] , but only about one-third of patients enrolled in the study returned for followup. Published data are lacking on use of levofloxacin and trovafloxacin for genital chlamydial infections.
Intra-abdominal infections. Comparative studies of treatment of intra-abdominal infections with quinolones have been published only with regard to ciprofloxacin and trovafloxacin.
Ciprofloxacin combined with metronidazole was compared with imipenem [54] , and trovafloxacin was compared with imipenem followed by amoxicillin-clavulanate [55] . Both studies were of a double-blind design. In the ciprofloxacin/metronidazole study, there were 2 arms for this therapy, 1 in which ciprofloxacin (400 mg b.i.d.) and metronidazole (500 mg q6h) were given completely intravenously and 1 in which patients could be switched from iv to oral medication (ciprofloxacin, 500 mg b.i.d.; metronidazole, 500 mg q6h). Imipenem was given at a dosage of 500 mg iv q6h.
Outcomes were similar in all 3 groups, with cure rates of 82% for ciprofloxacin/metronidazole iv, 85% for ciprofloxacin/ metronidazole iv/po, and 78% for imipenem. Outcomes correlated with APACHE (Acute Physiology and Chronic Health Evaluation) scores, and the mean APACHE scores were 9.2 in the ciprofloxacin/metronidazole groups and 10.5 in the imipenem group. Outcomes did not differ between treatment groups with different pathogens isolated, but failures were higher in all treatment groups among patients from whom enterococci were isolated than among those from whom enterococci were not isolated (28% vs. 14%). It is not clear whether these differences reflect limited efficacy of these agents against enterococcal infection or whether the presence of enterococci was a marker for patients with more severe infection.
In a similar study, trovafloxacin (initially 300 mg alatrofloxacin iv q.d. and then 200 mg trovafloxacin po q.d.) was compared with imipenem (1 g iv q8h) . APACHE scores also correlated with outcomes and were somewhat lower overall than in the ciprofloxacin study (6.4 for the trovafloxacin arm and 7.0 for the imipenem arm), possibly reflecting the dominance of patients with appendicitis in the study population. Outcomes were comparable, with 82% cures in both treatment groups. Clinical success rates did not differ by pathogen isolated, and in the subgroup of patients from whom B. fragilis was isolated, clinical responses seemed satisfactory with use of trovafloxacin (97% for trovafloxacin vs. 82% for imipenem).
Therefore the anaerobic activity of trovafloxacin appeared to be adequate in this patient population. The results of this study suggest that trovafloxacin may be used alone for mixed aerobic and anaerobic intra-abdominal infections but leaves uncertain its efficacy in more severely ill patients.
A similar regimen of iv followed by po trovafloxacin has also been compared with a regimen of cefotetan followed by amoxicillin-clavulanate for treatment of women with acute gynecologic infections, which were largely puerperal endomyometritis [56] . Clinical response rates were similar overall for the 2 regimens (96 [90%] of 107 vs. 102 [86%] of 119) and also did not differ in the smaller subgroups of patients from whom gramnegative aerobes, gram-positive aerobes, and anaerobes were isolated in cultures at study enrollment.
Skin and soft-tissue infections. Information is quite limited on the use of levofloxacin and trovafloxacin for treatment of patients with skin and soft-tissue infections. In a single published study, levofloxacin (500 mg q.d.) was compared with ciprofloxacin (500 mg po b.i.d.) for treatment of a group of patients in whom cellulitis (44%), pyodermas (11%), and cellulitis with abscess (11%) constituted the majority of infections [57] . The dominant pathogen was S. aureus (174 of 288 microbiologically assessable patients [60%]), and eradication rates were significantly higher for levofloxacin (100%) than for ciprofloxacin (87%).
Rates of eradication of S. pyogenes among the small number of patients from whom it was isolated were also high ( Trovafloxacin, which is active against a broad spectrum of pathogens, including anaerobic bacteria, was approved by the FDA for treatment of soft-tissue infections, including those in the feet of diabetic patients. No clinical data have been published, however, and no data are provided by the manufacturer in the package insert. Sparfloxacin and grepafloxacin have not been developed for treatment of skin and soft-tissue infections.
Respiratory tract infections. All 4 of the newest quinolones were developed and approved in the United States for treatment of patients with respiratory tract infections. In relation to pathogens involved in community-acquired infections, their potency, like that of ciprofloxacin and ofloxacin, is excellent for pathogens such as H. influenzae and M. catarrhalis, and their potency is also generally quite high for atypical pathogens, such as M. pneumoniae, C. pneumoniae, and Legionella species, with high intracellular concentrations of drug possibly augmenting activity in vivo against these latter pathogens.
S. pneumoniae was the principal pathogen about which there had been concerns with regard to the adequacy of the activity of earlier quinolones. Each of the newer agents exhibits improved potency against this pathogen. Published clinical data are now available concerning the use of levofloxacin, sparfloxacin, grepafloxacin, and trovafloxacin for treatment of several types of community-acquired respiratory tract infection. No data have been published on the use of any of these quinolones for treatment of nosocomial pneumonia, and only trovafloxacin has been approved by the FDA for this indication.
Acute bacterial exacerbations of chronic bronchitis (ABECB) are often associated with isolation of H. influenzae or M. catarrhalis from sputum, with a lesser occurrence of S. pneumoniae and enteric or nonenteric gram-negative bacteria. For treat-ment of patients with ABECB, rates of clinical improvement were similar for levofloxacin (500 mg po q.d. for 5-7 days) compared with cefuroxime axetil (250 mg po b.i.d. for 10 days) [58] and cefaclor (250 mg po t.i.d. for 7-10 days) [59] ; for sparfloxacin (200 or 400 mg on day 1 and then 100 or 200 mg q.d. for 7-14 days) compared with amoxicillin-clavulanate (500 mg/250 mg t.i.d. for 7-14 days) [60] and ofloxacin (400 mg b.i.d. for 10 days) [61] ; for grepafloxacin (400 mg or 600 mg q.d. for 7-10 days) compared with ciprofloxacin (500 mg b.i.d. for 10 days) [41] and amoxicillin (500 mg t.i.d. for 7-10 days) [62] ; and for trovafloxacin (200 mg or 100 mg q.d. for 5 days) compared with amoxicillin (500 mg t.i.d.) [63] and amoxicillinclavulanate (500 mg/125 mg t.i.d.) [64] .
Rates of eradication of specific pathogens from sputum were also generally similar, with the exceptions that sparfloxacin was significantly better than amoxicillin-clavulanate [60] and trovafloxacin was significantly better than amoxicillin [63] for eradication of H. influenzae. The extent to which resistance contributed to the inferior responses to the b-lactam comparator regimens was not documented in either study. In addition, in 1 study a trovafloxacin dosage of 200 mg q.d. was superior to a dosage of 100 mg q.d. in eradicating S. pneumoniae from sputum [63] . Resistance occurring in S. pneumoniae that persisted after quinolone therapy was not evaluated in this or other studies of treatment of patients with ABECB. None of these studies has evaluated the effect of treatment on the time to the next exacerbation of bronchitis, as was done in studies in which ciprofloxacin was shown to be superior to clarithromycin [65] and comparable with cefuroxime axetil [66] .
Community-acquired pneumonia involves an array of bacterial pathogens similar to those involved in ABECB, except that S. pneumoniae is usually the most frequently identified pathogen, and pathogens causing atypical pneumonia must also be considered in some patients. The greater severity of illness in some patients with pneumonia and in those with bacteremic pneumonia, in particular, also provides more stringent tests of the efficacy of quinolones than do studies of patients with ABECB. Because of rising resistance of pneumococci to penicillin and (to varying extents) other b-lactams [67] , fluoroquinolones with activity against S. pneumoniae have been recommended as a first-line option for treatment of patients with community-acquired pneumonia [68] .
Several randomized, comparative trials of treatment of such patients with the newest quinolones have been published, some of which have also been double-blind in design [69] [70] [71] [72] [73] . In each of these trials, clinical outcomes with the quinolones were similar or superior to those with use of comparator agents, for example, for levofloxacin (500 mg iv/po for 7-14 days) versus ceftriaxone (1-2 g iv q.d. or b.i.d. for 7-14 days) and/or cefuroxime axetil (500 mg po b.i.d.) [74] ; for sparfloxacin (400 mg on day 1 and then 200 mg q.d.) versus roxithromycin (150 mg b.i.d. for 10-14 days) [69] , high-dose amoxicillin (1 g t.i.d.) plus ofloxacin (200 mg b.i.d.) [70] , and high-dose amoxicillin alone (1 g t.i.d.) [71] ; for grepafloxacin (600 mg t.i.d.) versus amoxicillin (500 mg t.i.d.) [72] ; and for trovafloxacin (200 mg q.d.) versus high-dose amoxicillin (1 g t.i.d.) [73] .
Significantly better overall clinical response rates were seen for levofloxacin ( In the levofloxacin study, it was not possible to determine the relative proportions of patients in the ceftriaxone/ cefuroxime arm treated with ceftriaxone, cefuroxime, or both sequentially. In addition, although erythromycin was allowed in the ceftriaxone/cefuroxime arm for suspected atypical pneumonia at the discretion of the investigator and was given to 22% of patients in this treatment arm overall, it was not possible to assess to what extent it was used among those patients found to have atypical pathogens.
In the trovafloxacin study, although high-dose amoxicillin is commonly used in Europe for treatment of communityacquired pneumonia, it may be considered less than optimal against b-lactamase-producing strains of H. influenzae. There also remains uncertainty as to whether amoxicillin would be an optimal b-lactam in the face of increasing resistance to penicillin among pneumococci. Somewhat higher rates of eradication of H. influenzae were seen with levofloxacin, grepafloxacin, and trovafloxacin than with their comparators. Clinical responses in patients with S. pneumoniae infection were similar with sparfloxacin (vs. high-dose amoxicillin) and somewhat better with levofloxacin, grepafloxacin, and trovafloxacin than with their comparators.
In the small subgroups of patients with bacteremic pneumococcal pneumonia, whose illnesses probably are of greater severity and for whom there is greater certainty of the microbiological diagnosis (relative to diagnoses from sputum cultures alone), clinical responses to levofloxacin (9 of 9) and trovafloxacin (4 of 4) have been high. Among quinolones, the largest number of patients with bacteremic pneumococcal pneumonia have been treated with sparfloxacin, with a response rate of 82% (23 of 28) [69, 71] . In comparison, responses to high-dose amoxicillin (14 [88%] of 16) and roxithromycin (2 of 2) were somewhat higher, but the numbers were too small to be statistically significant.
There is considerably less information on the use of quinolones for treatment of patients with atypical pneumonia. Small numbers of patients with legionella pneumonia appear to have had good clinical responses to levofloxacin (5 of 5) [74] , sparfloxacin (1 of 1) [70] , and trovafloxacin (6 of 6) [73] , providing limited support to in vitro and animal data that have led to recommendations concerning use of quinolones for hospitalized patients with legionella infections [75] . Data on efficacy of quinolones for treatment of patients with atypical pneumonia caused by M. pneumoniae and C. pneumoniae are difficult to interpret because of the substantial response rates in the com-parator groups, which included agents not expected to have any activity against these pathogens in vivo.
This difficulty is highlighted by the results of 2 published trials. In the study of levofloxacin, rates of clinical response to levofloxacin were high for patients infected with M. pneumoniae (19 of 19) or C. pneumoniae (46 of 47) diagnosed by serological criteria. However, response rates were similarly high in the ceftriaxone/cefuroxime arm (22 of 22 for M. pneumoniae infections and 50 of 54 for C. pneumoniae infections) and did not differ whether or not these patients also received erythromycin [74] . Similarly, the clinical response rates reported for patients receiving trovafloxacin (15 of 16 for M. pneumoniae infections and 17 of 22 for C. pneumoniae infections) were similar to those for patients receiving amoxicillin (12 of 14 for M. pneumoniae infections and 24 of 26 for C. pneumoniae infections) [73] . Therefore, inaccuracies in serological diagnosis of these infections, unexpected clinical responses to b-lactams, or (most likely) substantial rates of spontaneous abatement of signs and symptoms could have contributed to these discrepancies. Studies designed to assess the time to resolution of symptoms may be needed to determine whether there is any clinical benefit in the use of quinolones for treatment of these types of atypical pneumonia.
Acute purulent sinusitis acquired in the community is often caused by a group of pathogens similar to those that cause ABECB and may be seen as a complication of viral upper respiratory infection. Anaerobic bacteria usually are present in only a small percentage of patients and are more likely to be noted if sinusitis is chronic or associated with dental infections. The use of nasal decongestants to establish drainage of the infected sinus cavity is an important adjunctive therapy, in addition to administration of antimicrobial agents. For treatment of patients with acute purulent sinusitis, levofloxacin (500 mg q.d.) has been compared with amoxicillin-clavulanate (500 mg/ 125 mg t.i.d.) [76] , and sparfloxacin (400 mg on day 1 and then 200 mg q.d.) has been compared with cefuroxime axetil (250 mg b.i.d.) [77] and clarithromycin (500 mg b.i.d.) [78] .
Clinical responses to levofloxacin and cefuroxime axetil were virtually identical when assessed 2-5 days after completion of a 10-to 14-day course of therapy. In a second noncomparative study that included analysis of sinus aspirates obtained by sinus puncture or nasal endoscopy to determine bacterial pathogens, a similar course of levofloxacin eradicated 93%-100% of pathogens, which were predominately H. influenzae ( ), S. n = 36 pneumoniae ( ), S. aureus ( ), and M. catarrhalis n = 32 n = 33 ( ) [79] . Similarly, sparfloxacin yielded clinical responses n = 15 that were virtually identical to those with use of cefuroxime axetil or clarithromycin in double-blind trials. Clinical response rates were similar in the subgroups in which H. influenzae, S. pneumoniae, and M. catarrhalis were isolated from drainage specimens from the middle meatus at the time of enrollment [77] .
There are no published trials of the use of grepafloxacin or trovafloxacin for treatment of patients with sinusitis. Levofloxacin and trovafloxacin received approval from the FDA for this indication, but until the issues of its hepatotoxicity risks are resolved, trovafloxacin should not be used for this indication. Thus levofloxacin may be an alternative to but offers no advantage over cefuroxime for treatment of acute communityacquired sinusitis. Empirical treatment of fever in patients with neutropenia. Early trials demonstrated that quinolones used as prophylaxis during periods of neutropenia were effective in preventing gram-negative bacteremia, but that streptococcal bacteremia occurred with increased frequency, particularly in bone marrow transplant recipients. Initial trials of quinolones as therapy for patients with fever and neutropenia had only limited success. There has, however, been a recent increase in interest in defining low-risk groups of neutropenic patients who might be safe candidates for oral antimicrobial therapy for fever, because of the potential for increased convenience and reduced costs.
Quinolones have been components of such oral regimens used in recent trials addressing this issue [80, 81] . Investigators evaluated a combination of oral ciprofloxacin and amoxicillinclavulanate compared with iv ceftazidime in 1 trial [81] and compared with iv ceftriaxone plus amikacin in the other [80] ; the subjects had fever and neutropenia from cancer chemotherapy but were able to take oral medications and, in general, were considered to be at low risk because of the absence of other diseases, absence of documented infection, and a projected duration of neutropenia of !10 days.
Rates of treatment success among patients given the oral and parenteral regimens were similar in both studies, although the oral regimen was associated with an unexpectedly higher incidence of adverse effects (16% vs. 1%), largely nausea and vomiting, in 1 study [81] . Renal failure, reported in an earlier trial of ciprofloxacin plus clindamycin for treatment of a similar group of patients, was not seen in these trials [82] . Whether oral therapy can also be safely translated into outpatient therapy for patients at rigorously defined low risk, however, remains to be determined. Although 2 feasibility trials of ofloxacin suggest that it may be possible to manage low-risk cases safely outside the hospital [83, 84] , the power of these studies to detect clinically important differences in preventable poor outcomes among such outpatients has been small, as was pointed out in a recent editorial accompanying the most recent studies [85] .
Bacterial Resistance Associated with Use of Quinolones
The selection pressures of exposure to antibiotics can promote the occurrence of resistance by providing a growth advantage for bacteria that have acquired exogenous resistance genes or for those bacteria in a population that contain spontaneous chromosomal resistance mutations. When resistance mechanisms result largely from acquisition of resistance genes (often on plasmids or other mobile genetic elements, e.g., ami-noglycoside resistance due to aminoglycoside-modifying enzymes) rather than by chromosomal mutation, selection pressures may have little effect until the requisite resistance genes have been introduced into the bacterial population under selection. Once the resistance gene has entered this population, however, there is an opportunity not only for clonal expansion but also for additional gene transfer among strains and species may occur.
In contrast, when resistance occurs largely by chromosomal mutation, all sufficiently large populations of bacteria will probably contain small numbers of spontaneously resistant mutants, which may then undergo clonal expansion under selective pressures.
Quinolone resistance in clinical settings appears to occur largely by chromosomal mutation [86] , although the extent to which the recently reported plasmid-mediated quinolone resistance found in several clinical isolates of Klebsiella pneumoniae has spread is unknown [87] . Chromosomal mutations have been of 2 general types: those that alter the subunits of the 2 quinolone target enzymes, DNA gyrase and topoisomerase IV, and those that affect drug permeation to these cytoplasmic targets by altering expression of porin-diffusion channels across the gram-negative outer membrane, altering expression of endogenous efflux pumps located in the inner membrane (also linked to proteins traversing the periplasm and outer membrane in gram-negative bacteria), or both types of alteration.
Individual mutations of both types cause distinct increments in resistance that may vary among different quinolones. For example, a common mutation in the A subunit of DNA gyrase of E. coli causes a 128-fold increase in the MIC of nalidixic acid (the oldest quinolone) but only a 4-fold to 8-fold increase in the MIC of ciprofloxacin and other fluoroquinolones. Similarly, a mutation that increases the expression of the NorA efflux pump of S. aureus increases resistance to ciprofloxacin by about 4-fold but has no effect on the activity of sparfloxacin. For most of the newer quinolones, in general, any single mutation causes a р16-fold increase in resistance.
Thus, if the therapeutic index (the ratio of quinolone concentration at the site of infection to the MIC for the pathogen) for a quinolone exceeds this factor, it is likely that the growth of spontaneous single-step resistance mutants will still be inhibited rather than selected by quinolone use. Therefore, use of low doses of quinolones or existence of pathogens at body sites in which drug delivery is poor may promote resistance by lowering the therapeutic index. Multiple mutations may also potentially accumulate when there are repetitive quinolone exposures for organisms that exist in reservoirs that allow persistence of early-step mutants.
During the past decade of use of ciprofloxacin and ofloxacin, different patterns of resistance in different pathogens have emerged. Most striking has been the rapid emergence of a high prevalence of quinolone resistance (190%) among methicillinresistant but not methicillin-susceptible strains of S. aureus in many parts of the world [88, 89] . This same difference in prevalence of quinolone resistance also exists between methicillinresistant and -susceptible strains of coagulase-negative staphylococci [90] .
For these organisms, several factors may have operated in concert. The delivery of drug in low concentrations to skin, sweat, and mucosa, the normal body-surface habitat of reservoirs of staphylococci, and a relatively low therapeutic index for drug concentrations in serum (about 3 for ciprofloxacin) probably contributed to ease of selection of individual resistant strains by quinolone exposure [91] . These factors, however, would have been expected to operate similarly for methicillinresistant and -susceptible strains. For methicillin-resistant strains, additional factors were probably operative to amplify the prevalence of quinolone resistance, including nosocomial spread of resistant strains [92] and coselection by exposure to any of several antibiotics because of the multidrug-resistance phenotype of the methicillin-resistant strains [90] .
For another pathogen with a similarly low therapeutic index, P. aeruginosa, the evolution of resistance has been substantial but more gradual [93] . Possibly, smaller endogenous reservoirs of these organisms and fewer opportunities for nosocomial spread have contributed to the more gradual increase in resistance.
Most surprising, however, has been the emergence of resistance in pathogens that are intrinsically highly susceptible to the modern quinolones, such that strains identified as resistant by break-point criteria of the clinical microbiology laboratory generally have 2 and in some cases multiple resistance mutations. These organisms include N. gonorrhoeae, E. coli, and Campylobacter jejuni. In the case of N. gonorrhoeae, outbreaks of resistant strains have been reported in isolated areas of the United States, but resistance has become highly prevalent in parts of the Far East [94] .
In 1 study in the United States, resistant strains were clonal and were less likely than susceptible strains to be detected by gram stains of urethral exudates, possibly contributing to reduced detection and fewer treatment regimens [95] . Intercity spread was also detected [96] . The relative extents to which quinolone use and clonal spread of resistant strains by sexual contacts contribute to the high prevalence of gonococcal quinolone resistance in other parts of the world is not certain.
For C. jejuni, quinolone resistance has emerged in Europe in parallel in both human and food-animal populations and was temporally associated with the use of quinolones in both populations [97] . Contamination of food products with resistant campylobacters has been demonstrated [98] , but the relative extent to which administration of quinolones to humans and animals contributed to resistance in these human populations has been uncertain. Recently, surveillance in the United States has identified an increase in domestically acquired cases of quinolone-resistant C. jejuni diarrhea in patients who had not previously received quinolone treatment [99] . This study also iden-tified substantial overlap in the resistant strain types of C. jejuni isolated from animal sources and those isolated from humans, linking human disease with animal sources of these pathogens.
Patients infected with resistant strains who were treated with quinolones were further shown to have slower-resolving diarrhea than patients infected with susceptible strains. Resistance has also been reported to have developed in a few patients during quinolone therapy for diarrhea caused by initially susceptible isolates of C. jejuni [100] . The diarrhea resolved but resistant organisms were shed in stool; no relapse of symptoms occurred.
Quinolone-resistant strains of E. coli have also emerged in Europe and have become prevalent in outpatients with UTIs, a particularly surprising circumstance not only because of the usually high susceptibility of the wild-type E. coli strains but also because of the high concentrations of many quinolones in urine, a combination of which should create exceptionally high therapeutic indices that would be expected to discourage emergence of resistance associated with quinolone use. Risk factors for acquisition of resistance in such patients in Spain have included use of quinolones, complicated infections, and use of urinary catheters [101] .
Clinically important resistance of E. coli has also developed in some hematology-oncology units in Spain and Germany in which quinolones were used as prophylaxis during periods of neutropenia [102, 103] , as well as in nonneutropenic patients in Spain [104] . In these units, breakthrough bacteremia with quinolone-resistant E. coli has become a problem. Such bacteremia and colonization of the fecal flora with quinoloneresistant E. coli [105] have been associated with quinolone use as prophylaxis and were caused by distinct strains, not clonal spread within the units. A few patients in these studies were noted, however, to have fecal colonization with resistant E. coli without prior quinolone exposure or hospitalization [105] .
Subsequently, a more extensive study of community fecal colonization with resistant E. coli in Spain has identified an unexpectedly high prevalence of 24%-26% among adults as well as children, for whom quinolones would not likely be used [106] . Also noteworthy were the findings in the earlier study of UTIs caused by quinolone-resistant E. coli. In that study, 14% of the isolates from control patients with UTIs due to fluoroquinolone-susceptible E. coli were resistant to pipemidic acid, an early-generation quinolone. This resistance, like that to nalidixic acid, is a more sensitive detector of first-step resistance mutations [101] . None of these control patients had a history of treatment with a quinolone, suggesting acquisition rather than selection as the source of the initial pipemidic acid-resistant strains.
These findings, in conjunction with earlier findings of high rates of colonization of poultry with resistant E. coli in Spain [107] , raise the possibility that contamination of the food supply with resistant E. coli may contribute to high baseline colonization rates in human fecal reservoirs. Furthermore, analysis of the resistant E. coli bloodstream isolates from patients with cancer identified strains with high levels of resistance, probably requiring multiple chromosomal mutations, an occurrence unlikely to have developed without several cycles of selection and persistence in vivo. Therefore, it is possible that these problems of resistance are the result of separate selection pressures acting on intersecting populations of bacteria.
First early-step mutant E. coli strains may have the opportunity to colonize the intestinal tracts of persons who have ingested contaminated food from animals that have been exposed to quinolones during production. When such persons are subsequently exposed to quinolones for treatment of UTIs, for prophylaxis during chemotherapy for cancer, or possibly for other indications, these early-step mutants may become the substrate from which selection of later, multistep highly resistant mutants becomes possible. It is noteworthy that the problems with resistant E. coli seen in Europe have not yet emerged in the United States, which has only recently allowed more limited use of quinolones in food-animal production.
As yet, the evidence suggesting a relationship between the high levels of resistant E. coli in humans and food animals in Europe is circumstantial; thus it will be important to perform epidemiological studies similar to those performed with resistant campylobacters to provide a link between resistant animal and human isolates, as well as further studies to provide a link between resistant E. coli in food-animal sources and the use of quinolones in production.
Quinolone resistance among respiratory pathogens has remained quite low, possibly because only recently has treatment of respiratory tract infections become a focus of quinolone use and possibly because the reservoir of some pathogens such as S. pneumoniae is children, a group in which quinolones have not been used routinely. Quinolone-resistant strains of S. pneumoniae, however, have been reported recently from Hong Kong [108] and Canada [109] , as has an increase in resistant isolates from older Canadians, from !1% in 1995 to 13% in 1998. No such increase in resistance was seen in isolates from Canadian children, a finding suggesting a relationship between quinolone use and the early emergence of resistance.
Particularly worrisome was the reported association of quinolone resistance with penicillin resistance in pneumococci, since it is for infections due to penicillin-resistant strains, which are commonly multiply resistant, that the need for alternative agents is most compelling. As quinolones become used more regularly for treatment of respiratory tract infections, surveillance for emerging resistance in respiratory pathogens will become increasingly important. Since still only a minority of S. pneumoniae strains in the United States are fully resistant to penicillin (10%-15%), it is reasonable to administer nonquinolone agents to many patients with mild disease and to reserve the newest quinolones for those patients whose conditions do not improve promptly with use of other agents and for patients with more severe disease, in whom any delay in initial response would have important clinical implications.
Routine use of quinolones to the exclusion of other agents for treatment of respiratory tract infections will probably create substantial selection pressures. Therefore, to minimize the risks for resistance, quinolones should be considered as 1 of several possible choices for treatment of bacterial respiratory tract infections and, like other antibiotics, should not be used for respiratory syndromes likely to be of viral origin. Continued avoidance of routine administration of quinolones to children will also probably be important for avoiding particularly highrisk selection pressure in a pneumococcal reservoir population. Further research will also be important to evaluate the impact of the choice of quinolone as well as dose and duration on the risk of resistance.
